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Background: To describe the characteristics of xerostomia (dry mouth) in the population with sleep apnea-hypop-
nea syndrome (SAHS) and contrast its prevalence versus that found in healthy subjects, and to compare the fre-
quency of xerostomia in SAHS patients with and without continuous positive airway pressure (CPAP) treatment.
Material and Methods: A prospective comparative study was made between adults recently diagnosed with SAHS 
in a public hospital (n=60) and healthy individuals (n=54). The presence of xerostomia was assessed on waking up 
and during the day, using a frequency scale from 0 (“never”) to 3 (“always”). 
Results: The prevalence of xerostomia on waking up in the SAHS group was 45%, versus 20.4% among the controls. 
During the rest of the day the prevalence of the symptom decreased in both the SAHS group (21.7%) and among 
the controls (9.3%). Multiple binary logistic regression analysis found body mass index (BMI) to be correlated to 
the association SAHS-xerostomia on waking up (p=0.007). Patients with moderate SAHS had a greater frequency 
of xerostomia than those with mild SAHS (p=0.022). The frequency of xerostomia on waking up was significantly 
greater in patients using CPAP than in those without such treatment (57.1% versus 16.7%, respectively) (p=0.008).
Conclusions: The frequency of xerostomia was greater in patients with SAHS, particularly on waking up and in 
those receiving CPAP. The symptom was more prevalent in individuals with moderate to severe SAHS than in those 
with mild SAHS, and was significantly influenced by BMI.
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Introduction
Sleep apnea-hypopnea syndrome (SAHS) is a major 
public health problem in view of its high prevalence 
and medical, social and economic impact (1). Total or 
partial interruption of breathing activity repeatedly du-
ring sleep causes hypoxia and sleep fragmentation, and 
is associated to cardiovascular, metabolic and neuro-
cognitive disorders (2). The condition affects 3-17% of 
the adult population (3) and is more common in males, 
obese individuals and menopausal women (4). The most 
frequent clinical manifestations are snoring and excessi-
ve daytime sleepiness. The gold standard for diagnosing 
and assessing the severity of SAHS is polysomnography 
(PSG) (5), based on the recorded apnea-hypopnea index 
per hour of sleep (AHI/h). The treatment of first choice 
for SAHS remains continuous positive airway pressure 
(CPAP) therapy (6). 
Dry mouth refers to a subjective sensation or oral dry-
ness (xerostomia) or to a genuine decrease in salivary 
flow (hyposialia) (7), and is a very common sensation in 
the general population, with a prevalence of 5-46% (8). 
Some diseases such as Sjögren syndrome or diabetes, as 
well as different drugs and local factors such as smoking 
or mouth breathing, may cause dry mouth (9).
In relation to sleep, xerostomia on waking up has been 
reported in patients with SAHS (10,11), and people with 
xerostomia have been described as having poorer qua-
lity sleep (12). Furthermore, dry mouth is described by 
many patients as a side effect of CPAP, and may adver-
sely affect adherence to therapy (13).
The present study describes the characteristics of xeros-
tomia in the population with SAHS and contrasts its pre-
valence versus that found in healthy subjects. In addi-
tion, it compares the frequency of xerostomia in SAHS 
patients with and without continuous CPAP.
Material and Methods
- Study design
A prospective case-control study was made of patients 
seen in Dr. Peset University Hospital (Valencia, Spain). 
The study complied with the guidelines of the Declara-
tion of Helsinki for medical research in humans, and was 
approved by the local Clinical Research Ethics Commit-
tee. Written informed consent was obtained from all par-
ticipating subjects.
We included patients between 25-75 years of age, with 
no relevant medical antecedents other than the disorders 
considered in the study, and who signed the correspon-
ding informed consent document. Patients with an ASA 
score of IV or higher were excluded, as were pregnant 
women and patients receiving pharmacological treat-
ment other than oral antidiabetic drugs in the last three 
months.
- SAHS group
The group of cases (with SAHS) consisted of patients 
from the Ear, Nose and Throat Department and Pneu-
mology Department with a recent (< 12 months) diag-
nosis of SAHS based on the polysomnography (PSG) 
or respiratory polygraphy (RP) findings, according to 
the criteria of the American Academy of Sleep Medi-
cine (AASM): AHI > 5/h plus associated symptoms, or 
AHI > 15/h. The AHI moreover evaluates the severity 
of SAHS, classifying it as mild (AHI: 5-14), moderate 
(AHI: 15-29) or severe (AHI ≥ 30). Within this group 
there was a subgroup of patients (70%) that had already 
started treatment with CPAP at the time of the explora-
tion.
- Control group
The control group (without SAHS) consisted of heal-
thy individuals acting as accompanying persons of pa-
tients visiting the Odontology Department. It included 
a subgroup of individuals (53%) in which the presence 
of SAHS was discarded based on objective parameters 
(respiratory polygraphy: AHI < 5/h) and another sub-
group of individuals (47%) in which SAHS was discar-
ded from the anamnesis (no snoring or daytime sleepi-
ness as evidenced by a score of < 10 on the Epworth 
scale). Likewise, there were three subjects, initially in-
cluded as controls, in which control respiratory polygra-
phic evaluation yielded AHI > 15/h.
- Anamnesis
Demographic data of all the participants were compiled, 
along with the general medical history (current and pre-
vious diseases, allergies, adverse drug reactions, regular 
medication and toxic habits: smoking and alcohol con-
sumption) and body mass index (BMI). With regard to 
the frequency of xerostomia, all the participants comple-
ted a questionnaire scoring the frequency of the symp-
tom on waking up and during the day, on a scale of 1-4 
(1 = “never”, 2 = “occasionally”, 3 = “quite often” and 
“4 = “always”). A score of ≥ 3 was taken to indicate the 
presence of xerostomia.
- Statistical analysis
A descriptive analysis of the study variables was carried 
out, with calculation of the mean and standard deviation 
(SD), minimum and maximum, and median for conti-
nuous variables, and of absolute and relative frequencies 
(percentages) for categorical variables. Analysis of the 
homogeneity of groups was made with the Student t-test 
for independent samples (age and BMI for continuous 
variables) and the chi-squared test (for categorical va-
riables). Simple binary logistic regression analysis was 
used to assess the probability of xerostomia, calculating 
the corresponding unadjusted (crude) odds ratio (OR) 
and 95% confidence interval (95%CI). Multiple regres-
sion analysis was used to adjust for independent varia-
bles (age and BMI). The level of statistical significance 
was established as 5% (α=0.05). The SPSS version 18.0 
statistical package (IBM SPSS Statistics Inc., Chicago, 
IL, USA) was used throughout.
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Results
The total sample comprised 114 patients (60 SAHS ca-
ses and 54 non-SAHS controls), of which were 57 males 
and 57 females, with a mean age of 52.9 ± 10.2 years. In 
the SAHS group, the mean AHI score was 24.9. Twen-
ty-five percent had mild SAHS, 40.0% moderate SAHS 
and 35.0% severe SAHS. On the other hand, 42 of the 
60 SAHS patients (70%) used CPAP. Since the study 
was conducted in the public hospital setting, other the-
rapeutic options, such as mandibular advancement devi-
ces (MADs), were not contemplated, since they are not 
financed by the Spanish national health system.
Table 1 shows some of the demographic and clinical 
characteristics of the study sample. The SAHS patients 
were comparatively older (SAHS: 55.4 ± 8.2 years; con-
trols: 50.1 ± 11.5 years; p=0.007), and had a greater BMI 
(SAHS: 29.9 ± 4.1 kg/m2; controls: 23.9 ± 2.9 kg/m2; 
p<0.001). In contrast, both groups were homogeneous in 
terms of gender distribution (p=0.708), diabetes mellitus 
(p=0.056), smoking (p=0.256) and alcohol consumption 
(p=0.248).
Table 2 reports the frequency of dry mouth sensation af-
ter nighttime sleep and during the day. Taking a score of 
≥ 2 as indicating the presence of xerostomia, the preva-





Smoking (yes/no) 0.256 (Chi2)
Degree of smoking habit in smokers 0.731 (Chi2)
Alcohol consumption (yes/no) 0.248 (Chi2)




Xerostomia on waking up Xerostomia during the day
no SAHS SAHS no SAHS SAHS
Total 54 (100.0%) 60 (100.0%) 54 (100.0%) 60 (100.0%)
1=Never 27 (50.0%) 27 (45.0%) 39 (72.2%) 29 (48.3%)
2=Occasionally 16 (29.6%) 6 (10.0%) 10 (18.5%) 18 (30.0%)
3=Quite often 7 (13.0%) 12 (20.0%) 4 (7.4%) 9 (15.0%)
4=Always 4 (7.4%) 15 (25.0%) 1 (1.9%) 4 (6.7%)
1+2=Absence 43 (79.6%) 33 (55%) 49 (90.7%) 47 (78.3%)
3+4=Presence 11 (20.4%) 27 (45%) 5 (9.3%) 13 (21.7%)
Table 1: Homogeneity of the SAHS and control groups according to their de-
mographic and clinical characteristics. Results of the chi-squared test (Chi2) 
and Student t-test (t) for independent samples.
Table 2: Frequency of xerostomia on waking up and during the day.
45% (95%CI: 32.4-57.6) (mild SAHS: 20.0%; modera-
te SAHS: 62.5%; severe SAHS: 42.9%), versus 20.4% 
among the controls (95%CI: 9.6-31.1). Twenty-five per-
cent of the patients with SAHS claimed to “always” ex-
perience the symptom on waking up, versus 7.4% of the 
controls. During the rest of the day, the dry mouth sensa-
tion decreased in both the SAHS group (21.7%; 95%CI: 
11.2-32.1) and among the controls (9.3%; 95%CI: 3.1-
20.3).
Initially, the patients with SAHS were estimated to 
have a 3.2-fold higher risk of xerostomia on waking up 
(p=0.006), and a 2.7-fold higher risk of experiencing 
xerostomia during the rest of the day (p=0.077). The 
association was therefore seen to be stronger when the 
symptom was evaluated after nighttime sleep. However, 
after adjusting for age and BMI, the analysis concluded 
that patient BMI was actually the factor explaining this 
association (p=0.007) (Table 3). We observed that for 
one same BMI, the difference in the probability of xe-
rostomia between the SAHS group and the controls was 
inexistent (p=0.934). During the day, the influence of 
BMI was less apparent (p=0.097).
With regard to the relationship between the severity of 
SAHS and the presence of xerostomia on waking up, we 
found moderate SAHS to be associated to a greater fre-
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Unadjusted odds ratio estimation; simple binary logistic regression analysis
Category OR 95%CI P-value
Group Control 1
SAHS 3.20 1.34 – 7.37 0.006**
Adjusted odds ratio estimation; multiple binary logistic regression analysis
Category OR 95% CI p-valor
Group Control 1
SAHS 1.05 0.34 – 3.22 0.934
Age 1.03 0.98 – 1.08 0.206
BMI 1.19 1.05 – 1.36 0.007**
*p<0.05; **p<0.01; ***p<0.001
Table 3: Correlation SAHS-xerostomia on waking up.
Adjusted odds ratio estimation; multiple binary logistic regression analysis 
Category OR 95%CI P-value
Group Mild SAHS 1 0.071
Moderate SAHS 6.23 1.30 – 29.8 0.022*
Severe SAHS 2.96 0.63 – 13.9 0.171
Age 1.02 0.95 – 1.09 0.581
BMI 1.17 0.99 – 1.38 0.065
*p<0.05; **p<0.01; ***p<0.001
Table 4: Correlation severity of SAHS-xerostomia on waking up.
quency of xerostomia than mild SAHS (p=0.022). In the 
case of severe SAHS, the association was less manifest 
(p=0.171) (Table 4). After adjusting for age and BMI, 
and despite the strong influence of BMI (p=0.065) - indi-
cating greater BMI to be correlated to an increased pro-
bability of xerostomia - the differences between mode-
rate and mild SAHS persisted (p=0.022). No differences 
were noted during the day (p=0.956).
In relation to the use of CPAP, on comparing the fre-
quency of xerostomia in the SAHS group between the 
patients with and without CPAP therapy, the preva-
lence was found to be 57.1% and 16.7%, respectively 
(p=0.008).
Discussion
The results of our study show that xerostomia, particu-
larly on waking up in the morning, is a common symp-
tom in patients with SAHS, and particularly in those 
receiving CPAP therapy. In 1985, Kales et al. (10) obser-
ved the presence of this symptom in 37 out of 50 patients 
with severe SAHS (74%).
In a later study of 668 patients scheduled for polysom-
nography, Oksenberg et al. (11) evaluated the presence 
of xerostomia in comparison with a series of 501 con-
trols. The authors recorded xerostomia on waking up 
in 31.4% of the patients finally diagnosed with SAHS 
(22.4%, 34.5% and 40.7% in those with mild, moderate 
and severe SAHS, respectively), versus in 16.4% of the 
primary snorers and in 3.2% of the controls. The pre-
valence of this symptom increased with the severity of 
SAHS. The patients reporting dry mouth on waking up 
had a 2.33-fold higher risk of SAHS than the primary 
snorers, and a higher risk of suffering severe SAHS 
(OR= 4.03; 95%CI: 1.94-8.4).
In the same way as in the aforementioned study (11), we 
recorded a higher prevalence of xerostomia on waking 
up in the group of patients with SAHS: 45% (95%CI: 
32.4-57.6) versus 20.4% in the control group (95%CI: 
9.6-31.1). However, after adjusting for patient age and 
BMI, we found BMI - not the diagnosis of SAHS - to be 
the true factor responsible for the increased frequency of 
xerostomia (p=0.007). Although other authors have re-
ported an increased incidence of salivary dysfunction in 
obese individuals (14,15), ours is the first study to iden-
tify BMI as the factor responsible for increased morning 
xerostomia among individuals with sleep apnea.
With regard to patient perception of the symptom during 
the day, the frequency of xerostomia in our sample was 
lower in both the SAHS group (21,7%) and among the 
controls (9,3%) than in either group on waking up in the 
morning (SAHS: 45%; controls: 20.4%). This seems lo-
gical, considering that salivary flow follows a circadian 
rhythm, with a marked drop during sleep (16). Moreo-
ver, in the SAHS group, the patients are largely mouth 
breathers (17), and therefore spend more time during ni-
ghttime sleep with the mouth open. 
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Previous studies in patients with SAHS have used scales 
to assess the frequency of a subjective symptom such 
as xerostomia (11,18). In our case we used the scale 
of Kreivi et al. (18), which scores the frequency of the 
symptom from 1-4, where 1 = “never”, 2 = “occasiona-
lly”, 3 = “quite often” and “4 = “always”. Likewise, we 
considered a patient score of 3-4 to indicate the presence 
of xerostomia. Oksenberg et al. (11) in turn used a simi-
lar scale with 5 degrees of frequency (“never”, “rarely”, 
“sometimes”, “often” or “almost always”). In contrast 
to our own study and that of Kreivi et al. (18), the men-
tioned authors only considered xerostomia to be present 
when the patient answered “almost always”. Possibly 
because of this stricter diagnostic criterion, the frequen-
cy of xerostomia on waking up in our study (45%) was 
greater than in that of Oksenberg et al. (31.4%).
On the other hand, López-Jornet et al. (12), in a sam-
ple of individuals previously diagnosed with hyposialia 
(unstimulated salivary flow < 0.2 ml/min), assessed di-
fferent self-administered questionnaires, including one 
instrument related to sleep quality (Pittsburgh Sleep 
Quality Index) and another addressing daytime sleepi-
ness (Epworth Sleepiness Scale). Dry mouth was found 
to be significantly associated to poorer sleep quality 
(p=0.006) and greater daytime sleepiness (p=0.010). 
With regard to the influence of CPAP, in our study the 
patients with SAHS that used this therapy presented a hi-
gher prevalence of xerostomia on waking up (57.1%) in 
comparison with the SAHS patients that did not use CPAP 
(16.7%). The positive airway pressure of CPAP causes dr-
ying of the exposed mucosal tissues, and the oral mucosa is 
no exception in this regard. This would explain the increa-
sed prevalence of dry mouth in CPAP users. In addition, a 
high incidence of oral symptoms has been reported in asso-
ciation to CPAP, particularly in diabetic patients (19). In the 
study published by Ulander et al. (13), dry mouth was the 
side effect most often associated to CPAP therapy. Never-
theless, other authors suggest that dry mouth or throat could 
be improved with the use of CPAP (18,20). Regarding whe-
ther or not the use of a humidifier with CPAP could im-
prove these symptoms, the data found in the literature are 
contradictory (18,21).
Based on the results obtained in our study, we can con-
clude that xerostomia is more frequent in individuals with 
sleep apnea than in healthy subjects - particularly when the 
symptom is assessed on waking up in the morning - and 
also in patients receiving CPAP therapy. In patients with 
SAHS, we found BMI to be significantly associated to an 
increased frequency of xerostomia. Likewise, xerostomia 
on waking up was more common in patients with moderate 
to severe SAHS than in patients with mild SAHS.
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